DIVISLAB's weekly performance was disappointing, with a return of -2.43%, indicating a decline in stock value. The stock's volatility was relatively high at 20.11%, suggesting significant price fluctuations. Compared to its peers, DIVISLAB outperformed DRREDDY but underperformed SUNPHARMA, and was on par with CIPLA. The stock's Sharpe ratio of -0.48 and max drawdown of -3.33% indicate a relatively high level of risk this week.

[Volatility: 20.11%]